Abstract-The metabolic fate of a new antiallergic agent, azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2H)-phthalazinone hydrochloride) in rats and guinea pigs was investigated using its 14C-labelled compound. The blood level of radioactivity reached the maximum at 1-1.5 hr after oral administration, indicating the rapid absorption of the drug from gastrointestinal tract. A high concentration of radioactivity was detected in the lung of both species following either oral or intravenous administration.
guinea pigs was investigated using its 14C-labelled compound.
The blood level of radioactivity reached the maximum at 1-1.5 hr after oral administration, indicating the rapid absorption of the drug from gastrointestinal tract. A high concentration of radioactivity was detected in the lung of both species following either oral or intravenous administration.
The major pathway of excretion of radioactivity was by way into feces, in both species. The radioactivity excreted in feces was attributable to that which was excreted in bile and exsorbed into gastrointegtinal tract. When the drug was given to pregnant rats, the concentration of radioactivity in the fetus was significantly lower than those in placenta and uterus, indicating the limited placental transfer of the drug. The successive oral administration of the drug in lower doses exerted no effect on the activity of microsomal drug-metabolizing enzymes of rat liver, while in higher doses, had a slight effect.
Azelastine (4-(p-chlorobenzyl)-2-[N-methylperhydroazepinyl-(4)]-1-(2)-phthalazinone hydrochloride) shown in Fig. 1 was newly synthesized as one out of several phthalazinone derivatives* and undergoing clinical trial in Japan. In pharmacological experiments azelastine showed strong and long-lasting antihistaminic and strong antiallergic efficacies (in preparation by Asta-Werke AG, Bielefeld and Eisai, Tokyo).
Recently, Tasaka and Akagi (1) reported that when the nasal decongestant effect of azelastine was compared with effects of clemastine and diphenhydramine by means of the nasal impedance method (2), azelastine was at least as effective as above two antihistaminic agents. In addition, they provided evidence that azelastine had the long lasting antihistaminic effect in the case of isolated guinea pig ileum, and the drug, like diphenhydramine and mepyramine, released histamine from the rat mesentery at a higher concentration, but inhibited istration of the drug (1 mg/kg) in rats and guinea pigs, respectively, indicating that the decay curves were similar in both species during at least the first 8 hr after medication.
Tissue distribution: After oral administration of 14C-azelastine to rats (10 mg/kg) or guinea pigs (1 mg/kg), the tissue distribution of radioactivity was examined. As shown in Tables 1 and 2 , the radioactivity was detected in all of 14 tissues of both species. At 1 hr after medication, a relatively high radioactivity was found in the small intestine, stomach, lung and liver. After 6 hr, the highest radioactivity was detected in the lung of both species, and after 24 hr, in the liver of rats and in the lung of guinea pigs.
After intravenous administration of the drug (1 mg/kg), the radioactivity was also detected in all tissues tested as shown in Tables 3 and 4 . At 1 hr after medication, the highest radioactivity was found in the lung and after 6 and 24 hr, a relatively higher radioactivity was observed in the lung and liver of both species.
The tissue distribution of radioactivity in rats was also examined 24 hr after successive oral administration of the drug for 7, 14 and 21 days (10 mg/kg/day). As shown in Table 5, the radioactivity in the tissues tested was higher on the 14th day than on the 7th day, suggesting that there was still some amount of the drug in the rat body, although the radioactivity was rather lower on the 21st day compared with that on the 14th day. At each time, the highest radioactivity was observed in the liver.
Urinary and fecal excretion: After oral administration of 14C-azelastine to rats (10 mg/ kg) and guinea pigs (1 mg/kg), the urine and feces were collected over a period of 7 days and daily samples were counted for radioactivity. As shown in Table 6 , most of the radioactivity was recovered during the first 2 days after administration and the major pathway of excretion was into the feces in both species, especially in rats.
In addition, the excretion rates of radioactivity after i.v. administration of the drug
(1 mg/kg) to rats and guinea pigs are shown in Table 7 . In these cases, the urinary excretion rates in both species were somewhat higher than after the p.o. administration described above. Values represent means of four animals.
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Biliary excretion: After p.o. or i.v. administration of 14C-azelastine (1 mg/kg), the bile was collected from the rats with a biliary fistula over a period of 2 days. The aliquots of 0-24 hr and 24-48 hr bile were counted for radioactivity. In addition, the gastrointestinal tract was isolated at 48 hr after medication and homogenized together with its contents.
An aliquot of homogenate was counted for radioactivity, as described in Methods.
As shown in Table 8 , the radioactivity given was almost completely recovered from bile, and gastrointestinal tracts and its contents. These data were consistent with the facts that when the drug was given to rats p.o. or i.v., the radioactivity was mainly excreted in the feces (Table 6 and 7 ).
An additional experiment was carried out in order to examine the effect of dose levels on biliary excretion of 14C-azelastine. When the drug was administered p.o. in a dose of 10 mg/kg, the recovery of radioactivity in bile was 45.3 % and 4.7 % for 0-24 hr sample and 24-48 hr sample, respectively. These values were nearly equal those obtained with a dose of 1 mg/kg, as shown in Table 8 .
Placental transfer: Table 9 shows the distribution of radioactivity in fetus, placenta and uterus following oral administration of 14C-azelastine (1 mg/kg) to pregnant rats. In all of the samples, the radioactivity was detected at 2,6 and 24 hr after medication. However, the concentration of radioactivity in the fetus was significantly lower than those in the placenta and uterus, indicating the limited placental transfer of azelastine and its metabolites. Effect on activity of hepatic microsomal drug-metabolizing enzymes : A study was done to determine whether successive oral administration of non-labelled azelastine to rats for 1 week influences the activities of aminopyrine N-demethylase and aniline hydroxylase and the contents of cytochrome P-450 and protein in liver microsomes. The results are shown in Table 10 .
At a dose of 10 mg/kg/day, little change was observed in those activities and contents, whereas at a dose of 50 mg/kg/day there was a slight increase in the activity of aminopyrine N-demethylase and the content of cytochrome P-450. On the other hand, when phenobarbital sodium was given intraperitoneally to rats at a dose of 70 mg/kg/day for 3 days, aminopyrine N-demethylase activity increased about 1.6 fold, cytochrome P-450 content about 3.7 fold and protein content about 1.5 fold, compared with those of the control.
From these results, it was concluded that successive oral administration of azelastine in lower doses exerts no effect on the activity of hepatic microsomal drug-metabolizing enzymes, while in higher doses, it has a slight effect.
DISCUSSION
In rats and guinea pigs, the blood levels of radioactivity rose quickly following oral administration of 14C-azelastine. This fact indicates that the drug is readily absorbed from the gastrointestinal tracts of both species. Furthermore, the present study showed that after oral or intravenous administration the radioactivity was mainly recovered in the feces of these animals. To elucidate how much of the radioactivity in feces was attributable to that excreted into the bile, the biliary excretion of the radioactivity given was investigated using the rats with a biliary fistula. As a result, high biliary excretion rates of radioactivity were observed, as shown in Table 8 . The relatively high molecular weight (381.9) of this drug appears to facilitate biliary excretion, because a molecular weight greater than 300 is necessary for high biliary excretion (6). In addition, attention must be given to the exsorption of drugs, i.e. the transport of drugs from blood to gastric or intestinal lumen across the membrane. Organic bases (7-10) were exsorbed into the stomach, and sulfanilamide derivatives (11-14) or dieldrin (6) into the small intestinal lumen. The present study showed that when 14C-azelastine was given i .v. to the rats with a biliary fistula, about 20 % of the radioactivity 
